Theravance Biopharma is a biopharmaceutical company whose commercial focus includes YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of COPD in the U.S. The product is partnered for commercialization, with economics tied to U.S. profit-sharing and royalties rather than a large owned sales force alone. The company concentrates on respiratory medicine and related partnered assets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 15.4 | — | -13.6 | — |
| Q2 2025 | 26.2 | — | 54.8 | — |
| Q3 2025 | 20 | — | 3.6 | — |
| Q4 2025 | 45.9 | — | 61 | — |
| Q1 2026 | 17.7 | 15% | -4.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ADS-TEC Energy PLC (ADSE), Bloomin' Brands, Inc. (BLMN), Mako Mining Corp. (MAKO), Sabre Corporation (SABR), Adamas Trust, Inc. (ADAM), Backblaze, Inc. (BLZE)